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Endogenous molecules generated upon pathogen
invasion or tissue damage serve as danger signals
that activate host defense; however, their precise
immunological role remains unclear. Tenascin-C is
an extracellular matrix glycoprotein that is specifi-
cally induced upon injury and infection. Here, we
show that its expression is required to generate an
effective immune response to bacterial lipopolysac-
charide (LPS) during experimental sepsis in vivo.
Tenascin-C enables macrophage translation of
proinflammatory cytokines upon LPS activation of
toll-like receptor 4 (TLR4) and suppresses the
synthesis of anti-inflammatory cytokines. It mediates
posttranscriptional control of a specific subset of
inflammatory mediators via induction of the micro-
RNA miR-155. Thus, tenascin-C plays a key role in
regulating the inflammatory axis during pathogenic
activation of TLR signaling.INTRODUCTION
The danger theory of immunity changed the way we think about
host defense; defining the immune system as the primary
response not only against infection but also against sterile tissue
injury (Matzinger, 1994). The identification of evolutionarily
conserved ‘‘pattern-recognition’’ receptors (PRRs) and their
ability to sense ‘‘danger signals’’ generated upon infection
(pathogen-associated molecular patterns [PAMPs]) and tissue
injury (damage-associated molecular patterns [DAMPs]), and in
response to activate inflammatory signaling pathways, has
further delineated the molecular machinery that drives immunity
(Beutler, 2007; Gordon, 2002; Medzhitov and Janeway, 2002).
DAMPs have been defined as endogenous molecules specif-
ically generated upon tissue damage. They comprise a variety of
proteins, proteoglycans, and fatty acids, including intracellular
molecules released from necrotic cells, extracellular matrix
(ECM) fragments created by tissue destruction, and ECM mole-
cules whose expression is specifically induced upon tissue injury
(Bianchi, 2007; Gordon, 2002). Physiologically committed to
alerting the body to damage and initiating tissue repair, even in914 Cell Reports 2, 914–926, October 25, 2012 ª2012 The Authorsthe absence of microbial invasion, DAMPs can directly induce
an inflammatory response via activation of PRRs (Chen and
Nun˜ez, 2010). They do so in a manner distinct to PAMP-
mediated activation of PRRs in order to drive unique cellular
responses (Midwood et al., 2009; Osterloh et al., 2007; Silva
et al., 2007).
However, DAMPs are also generated uponmicrobial infection.
An emerging feature of infectious disease is that levels of endog-
enous danger signals typically associated with tissue injury are
also rapidly elevated upon pathogen invasion. For example,
the nuclear DNA-binding protein HMGB1 is promptly released
from infected cells (Lotze and Tracey, 2005), and expression of
the glycoprotein tenascin-C is induced upon infection, often
appearing before any obvious sign of tissue damage (Midwood
andOrend, 2009). Although levels of DAMPs are tightly regulated
during acute inflammatory responses to infection and are
cleared after the microbial threat has been eliminated, persis-
tently high levels occur in patients with sepsis (Piccinini and
Midwood, 2010; van Zoelen et al., 2009; Yang et al., 2004), the
clinical manifestation of a dysregulated immune response to
infection, which accounts for9% of the overall annual mortality
in the USA (Angus et al., 2001). Consistent with these data,
PAMPs can directly induce the expression of endogenous
danger signals in vitro. For instance, respiratory syncytial virus
infection induces intracellular Hsp72 secretion in airway epi-
thelial cells (Wheeler et al., 2009). Furthermore, tenascin-C,
S100A8/S100A9, biglycan, and HMGB1 are secreted by
macrophages following stimulation with Gram-negative bac-
terial lipopolysaccharide (LPS) (Ehrchen et al., 2009; Goh
et al., 2010; Schaefer et al., 2005; Wang et al., 1999). These
data imply a role for DAMPs not only in mediating tissue repair
upon injury but also driving inflammation during pathogenic
infection. During microbial invasion, these molecules may
amplify inflammatory signals by directly activating PRRs
(El Mezayen et al., 2007; van der Poll and Opal, 2008); however,
their role in infection-induced inflammatory signaling remains
largely undefined.
Here, we identify a unique role for the danger signal tenascin-C
in regulating immunity mediated by toll-like receptor 4 (TLR4) in
response to pathogenic infection. Tenascin-C is an ECM glyco-
protein that is absent in most healthy adult tissues but that is
specifically expressed upon tissue injury (Chiquet-Ehrismann
and Chiquet, 2003) as well as during infection (Kaarteenaho-
Wiik et al., 2000; Pa¨a¨llysaho et al., 1993). Levels are high in
patients with sepsis (Schenk et al., 1995). In vitro, LPS activation
of TLR4 transiently induces tenascin-C expression in human
myeloid cells (Goh et al., 2010). Our data show that tenascin-C
is required for the proinflammatory response to LPS in vivo. Tar-
geted deletion of tenascin-C impairs TNF-a production and
subsequent downstream cytokine synthesis, in response to
LPS in septic mice and bone marrow-derived macrophages
(BMDMs). We also provide mechanistic insights into tenascin-
C-dependent signaling downstream of LPS activation of TLR4
and demonstrate that tenascin-C operates posttranscriptionally,
modulating levels of TNF-a translation. Moreover, we found
that tenascin-C mediates this control through the induction of
miR-155, a microRNA (miRNA) whose expression is strongly
induced by LPS in macrophages (O’Connell et al., 2007; Tili
et al., 2007), and that positively regulates the production of
TNF-a (Bala et al., 2011; Tili et al., 2007). Our study identifies
tenascin-C as a regulator of the early immune response and
shows that an effective and coordinated inflammatory response
to pathogenic activation of TLRs requires the participation of
endogenous danger signals.
RESULTS
Tenascin-C Is Required for the Proinflammatory
Response to LPS In Vivo
To examine the role of tenascin-C in host defense against
pathogenic infection, we induced sepsis with a sublethal dose
of LPS in tnc+/+ and tnc/ mice. The major clinical symptoms
of sepsis, including weight loss, reduced mobility, uveitis, ruffled
fur, and diarrhea, were evident in tnc+/+mice 1.5 hr after injection
of LPS, in contrast to tnc/ mice, which showed no symptoms
by 1.5 hr. Although symptoms became progressively more
severe in tnc+/+ mice 4 and 8 hr after injection, tnc/ mice
exhibited significantly less weight loss (p < 0.0001 at 4 hr;
p = 0.0006 at 8 hr), less mobility impairment (p < 0.0001 at
4 and 8 hr), and less fur ruffling (p < 0.0001 at 4 and 8 hr) than
tnc+/+ mice, with mild uveitis and diarrhea (Figures 1A, 1B,
S1A, and S1B).
On the molecular level, sepsis is driven by a ‘‘cytokine storm’’
comprising elevated circulating levels of proinflammatory cyto-
kines induced in response to LPS. Analysis of plasma levels of
key inflammatory mediators of sepsis showed that tnc/ mice
synthesize significantly less TNF-a (p < 0.0001) and IL-6 (p <
0.0001) compared to tnc+/+ mice 1.5 hr after LPS injection,
consistent with the lack of clinical symptoms in the absence of
tenascin-C. By 4 hr, there was significantly less TNF-a (p =
0.001) in tnc/ mice compared to tnc+/+ mice. Plasma TNF-a
and IL-6 dropped by 8 hr similarly in both tnc/ and tnc+/+
mice. Furthermore, tnc/ mice fail to induce release of
HMGB1, a late mediator essential for organ damage in sepsis
(Wang et al., 1999), which was significantly increased in tnc+/+
mice 8 hr after LPS injection (Figure 1C).
Tissue damage following systemic LPS injection results from
immune cell recruitment to susceptible sites, most notably, rapid
neutrophil infiltration to lungs and liver. Immunohistochemical
staining of neutrophil elastase in lungs and liver from tnc+/+
mice 1.5 hr after LPS injection demonstrated substantial neutro-
phil infiltration, which was significantly reduced in tnc/ mice,Can effect also evident at 4 and 8 hr after injection (Figures 1D,
S1C, and S1D).
To determine whether tenascin-C expression is elevated in
mice with LPS-induced sepsis, we quantified plasma tenascin-
C in tnc+/+ mice after LPS injection. Immunoblot analysis and
ELISA revealed increased tenascin-C in mice upon administra-
tion of LPS. Notably, the kinetics of tenascin-C expression was
similar to the early proinflammatory cytokines TNF-a and IL-6,
peaking 1.5 hr after LPS injection and decreasing over time
(Figures 1E–1G). Together, these results indicate that tenascin-
C expression is required for the proinflammatory response to
LPS in vivo.
Bone Marrow Engraftment Rescues TNF-a Synthesis
in Tnc/ Mice
TNF-a was the cytokine most affected by tenascin-C ablation.
To determine if the reduced plasma levels of TNF-a observed
in tnc/ mice are mediated by defects in their hematopoietic
cell population, we performed allogeneic bone marrow trans-
plantation. Whole bone marrow cells isolated from tnc+/+
or tnc/ male mice were injected into sublethally irradiated
tnc+/+ or tnc/ female recipient mice. Tnc+/+/+/+, tnc+/+//,
tnc///, and tnc//+/+ chimeric mice were generated. All
mice displayed equally high donor engraftment as shown
by quantitative RT-PCR analysis of the mouse testis-specific
Y-encoded protein (TSPY) gene in erythrocyte-depleted periph-
eral blood cells from recipient mice (Figure 2A). These data
indicate that the majority of bone marrow cells are from the
donor.
Analysis of tenascin-C mRNA in peripheral blood cells from
tnc+/+// mice 1.5 hr after LPS injection showed significantly
reduced expression of tenascin-C compared to tnc+/+/+/+ mice.
The tenascin-C mRNA observed in tnc+/+// mice is likely
produced by residual bone marrow cells of the tnc+/+ recipient.
Replenishment of tnc/ mice with tnc+/+ bone marrow resulted
in significantly more tenascin-C expression compared to
tnc/// mice (Figure 2B).
TNF-a levels in plasma from tnc+/+// chimeric mice were
significantly lower (p = 0.0033) than those from tnc+/+/+/+
chimeric mice 1.5 hr after LPS injection (Figure 2C). Accordingly,
significantly more TNF-a (p < 0.0001) was found in plasma from
tnc//+/+ chimeric mice compared to tnc/// chimeric mice
(Figure 2D). Eight hours after LPS injection, TNF-a was reduced
almost to basal levels in each group. Collectively, these data
indicate that tenascin-C derived from bonemarrow-derived cells
drives TNF-a synthesis during LPS-induced sepsis and that
bone marrow-derived cells from tnc/ mice exhibit defects in
TNF-a synthesis in vivo.
LPS-Activated BMDMs Express Tenascin-C
We next investigated whether primary BMDMs obtained from
tnc+/+ mice express tenascin-C in response to LPS over time.
Nonstimulated cells showed low basal levels of tenascin-C
expression, which significantly increased upon stimulation with
LPS. Tenascin-C mRNA started to increase at 1 hr and peaked
between 4 and 8 hr, returning to basal levels by 24 hr (Figure 3A),
as observed in human myeloid cells (Goh et al., 2010). Increased
tenascin-C mRNA correlated with tenascin-C protein synthesis.ell Reports 2, 914–926, October 25, 2012 ª2012 The Authors 915
Figure 1. Tnc/ Mice Are Less Susceptible to LPS-Induced Sepsis
(A and B) Body weight (A) and mobility (B) loss in tnc+/+ and tnc/mice upon LPS injection, monitored over 8 hr. Data in (A) are presented as percent loss relative
to noninjectedmice (n = 17 (A) or 10 (B) mice per group; mean ±SEM). ****p < 0.0001 and ***p < 0.001 compared to noninjectedmice (A). Data are from three (A) or
two (B) independent experiments.
(C) Time course analysis of TNF-a, IL-6, and HMGB1 in plasma from tnc+/+ and tnc/mice after LPS injection by ELISA (n = 3–5 mice per group; mean ± SEM).
****p < 0.0001, ***p < 0.001, and ** p < 0.01. Data are representative of three independent experiments.
(D) Immunohistochemical analysis of neutrophil elastase+ cell infiltration in lungs from tnc+/+ and tnc/ mice 0, 1.5, 4, and 8 hr after LPS injection (n = 4 LPS-
injected and 3 noninjected mice per genotype). Scale bars, 100 mm. Data are representative of three independent experiments.
(E and F) Immunoblot analysis of plasma tenascin-C (TN-C) in tnc+/+ (one to three) and tnc/ (four to six) mice 8 hr (E) and 0, 1.5, 4, and 8 hr (F) after LPS injection.
Results are representative of three independent experiments.
(G) ELISA of plasma tenascin-C in tnc+/+ mice 0, 1.5, 4, and 8 hr after LPS injection (n = 7; mean ± SEM). Data are from two independent experiments.
Related to Figure S1.
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Figure 2. Allogeneic Bone Marrow Trans-
plantation Rescues LPS-Induced Circu-
lating TNF-a in Tnc/ Mice
(A) Quantification of male donor cell engraftment in
female recipients 8 weeks after bone marrow
transplantation by quantitative RT-PCR analysis of
mouse TSPY gene in erythrocyte-depleted
peripheral blood cells. Data are shown as per-
centage of donor chimerism relative to that of
male control mice.
(B) Quantitative RT-PCR analysis of tenascin-C
mRNA in erythrocyte-depleted peripheral blood
cells of female recipients 1.5 hr after LPS injection.
Results are presented relative to those of tnc+/+/+/+
chimeric mice. *p < 0.05 compared to tnc+/+/+/+
chimeric mice.
(C and D) ELISA of TNF-a in plasma from tnc+/+/+/+
and tnc+/+// (C) and tnc/// and tnc//+/+ (D)
chimeric mice 1.5 and 8 hr after LPS injection.
Results represent measurements of three mice
per group (mean ± SD). ****p < 0.0001 and
**p < 0.01.Nonstimulated BMDMs produced no detectable tenascin-C;
however, cell-associated tenascin-C significantly increased
after LPS activation, peaking 8 hr after stimulation (Figure 3B).
Tenascin-C was also secreted into the medium where its levels
significantly increased 24 hr after stimulation (Figure 3C). These
data demonstrate that tenascin-C expression in BMDMs is
transiently induced by LPS.
To verify that tenascin-C ablation does not affect macrophage
development in vitro and in vivo, we assayed tnc+/+ and tnc/
BMDMs or freshly isolated peritoneal macrophages for CD11b,
F4/80, and CD68 expression. Each maturation marker was
equally highly expressed in tnc+/+ and tnc/ cells (Figures
S2A–S2O).
Tenascin-C Posttranscriptionally Regulates
LPS-Mediated Synthesis of Specific Cytokine
Subsets in BMDMs
To further examine the mechanism behind impaired proinflam-
matory cytokine synthesis in tnc/ mice upon LPS treatment,
we investigated the effects of tenascin-C on cytokine synthesis
in BMDMs. There was no significant difference in IL-1b, IL-12,
and TGF-b1 secretion between tnc+/+ and tnc/ BMDMs.
However, BMDMs obtained from tnc/ mice secreted sig-
nificantly less TNF-a, IL-6, and CXCL1, and significantly more
IL-10, upon stimulation with LPS than tnc+/+ cells (Figure 4A).
The expression of TNF-a, IL-6, CXCL1, and IL-10 mRNA was
induced in tnc+/+ BMDMs by LPS stimulation and was not signif-
icantly affected by tenascin-C ablation (Figure 4B). No difference
in IL-12 and TGF-b1 mRNA expression was observed in tnc+/+
and tnc/ BMDMs (data not shown). These results suggestCell Reports 2, 914–926,that regulation of cytokine synthesis by
tenascin-Coccursat aposttranscriptional
level.
To ensure that the effect of tenascin-C
on cytokine synthesis is not due to
abnormal macrophage activation in vitroor in vivo, we analyzed the expression of activation markers in
tnc+/+ and tnc/ BMDMs or freshly isolated peritoneal macro-
phages. Equal expression of MHC II, CD40, or CD86 and the
LPS receptor TLR4/MD2 was observed in tnc+/+ and tnc/
BMDMs (Figures S3A–S3J) or peritoneal macrophages (data
not shown).
Tenascin-C Promotes Translation of Proinflammatory
Cytokines
Impaired proinflammatory cytokine production without any
reduction in cytokine mRNA levels in tnc/ cells led us to inves-
tigatewhether tnc/BMDMsexhibit abnormal intracellular cyto-
kine levels as a consequence of deficient secretion. There was
no significant difference in cellular TNF-a, IL-6, andCXCL1 levels
in LPS-stimulated tnc+/+ and tnc/ BMDMs (Figure 5A). Cyto-
kine levels in the cellular fraction did not account for the defec-
tive cytokine secretion by tnc/ BMDMs, as shown by the sum
of the amounts of cellular and secreted protein fractions (Fig-
ure 5B). These data demonstrate that proinflammatory cytokine
cellular trafficking occurs normally in tenascin-C null BMDMs.
We next investigated whether tenascin-C affects proinflam-
matory cytokine translation. Brefeldin A, an inhibitor of ER-to-
Golgi protein transport, resulted in intracellular accumulation
of TNF-a, IL-6, and CXCL1 in tnc+/+ cells at 24 hr. In contrast,
intracellular accumulation of TNF-a was abrogated in tnc/
BMDMs. Significantly less IL-6 and CXCL1 also accumulated
within the Golgi in tnc/ BMDMs (Figure 5C). Together, these
results provided the first clue that tenascin-C may be required
for effective translation of LPS-induced proinflammatory cyto-
kines in BMDMs.October 25, 2012 ª2012 The Authors 917
Figure 3. Tenascin-C Expression Is Transiently Induced by LPS
(A) Quantitative RT-PCR analysis of tenascin-C mRNA in BMDMs stimulated for 1, 1.5, 4, 8, 24, and 48 hr with 100 ng/ml LPS. Results are presented relative to
those of untreated BMDMs. Data are from seven independent experiments (mean ± SEM). ***p < 0.001 and **p < 0.01 compared to nonstimulated cells.
(B) ELISA of cellular tenascin-C in BMDMs stimulated for 1.5, 4, 8, 24, 48, and 72 hr with 100 ng/ml LPS. Results are normalized to the cell number. Data are
from six independent experiments (mean ± SEM). ***p < 0.001 compared to nonstimulated cells.
(C) ELISA of secreted tenascin-C by BMDMs stimulated for 1.5, 4, 8, 24, 48, and 72 hr with 100 ng/ml LPS. Data are from six independent experiments
(mean ± SEM). **p < 0.01 and *p < 0.05 compared to nonstimulated cells.
See also Figure S2.Tenascin-C Drives LPS-Induced miR-155 Expression
Protein translation is regulated on several levels, among which
miRNAs are key regulators of protein synthesis. Recent data
have highlighted the importance of miRNA-mediated control of
LPS-induced inflammatory signaling pathways (O’Neill et al.,
2011); therefore, we investigated whether tenascin-C affects
miRNA activity. miRNA expression in tnc+/+ and tnc/ BMDMs
stimulated with LPS for 8 hr was analyzed with an array contain-
ing 375 miRNAs. We found 35 miRNAs that were reproducibly
and significantly up- or downregulated by LPS (Figure 6A). A
number of miRNAs have emerged as important regulators of
TLR signaling, including those induced by LPS activation of
TLR4 (O’Neill et al., 2011). Among these, we found expression
of early-response genes such as miR-155, miR-125b, and let-
7i (Figure 6B) as well as late-response genes, including miR-
146a, miR-132, and miR-21 (Figure 6C). In tnc+/+ BMDMs, LPS
strongly induced miR-155 expression, which was significantly
inhibited in tnc/ cells (Figures 6A and 6B). Using quantitative
RT-PCR, we confirmed these results and showed that miR-155
expression was rapidly induced by LPS, peaking at 24 hr and
progressively declining in tnc+/+ BMDMs. Conversely, LPS-
induced miR-155 expression in tnc/ BMDMs was inhibited
and did not recover (Figure 6D). Furthermore, analysis of the
primary transcript pri-miR-155 in the same samples revealed
no significant difference between tnc/ and tnc+/+ BMDMs,
which suggests that tenascin-C posttranscriptionally regulates
LPS-induced miR-155 expression. In line with studies showing
that miR-155 expression is induced immediately after LPS
stimulation (O’Connell et al., 2007) and contributes to TNF-a
production (Bala et al., 2011; Tili et al., 2007), changes in
TNF-a levels and miR-155 expression significantly correlated in
LPS-stimulated tnc+/+ BMDMs. Accordingly, low TNF-a levels
correlated with low miR-155 expression in tnc/ BMDMs
(Figure 6E). This effect was specific because IL-6, CXCL1, and
IL-10 synthesis did not correlate with miR155 expression (p =
0.233; data not shown). To determine whether these data are
relevant in vivo, we examined the expression of LPS-induced918 Cell Reports 2, 914–926, October 25, 2012 ª2012 The AuthorsmiR-155 in the spleen of tnc+/+ and tnc/ mice upon LPS
injection. Tnc/ mice expressed significantly less miR-155
than tnc+/+ mice (Figure 6F). Taken together, these data suggest
that tenascin-C is required for the induction of miR-155 by LPS
in BMDMs and in septic mice.
Tenascin-C Controls TNF-a Release via the Induction
of miR-155
To determine whether reconstituting miR-155 expression
rescues LPS-induced TNF-a production in the absence of tenas-
cin-C, we overexpressed the mature miRNA in tnc/ BMDMs.
Cells were transiently transfected with a negative control
precursor or miR-155 precursor, which mimics the endogenous
precursor miR-155. Transfection of miR-155 precursor, but not
control precursor, resulted in increased expression of mature
miR-155. Stimulation of transfected tnc/ BMDMs with LPS
for 8 hr led to increased miR-155 expression, at a level similar
to that induced by LPS in control tnc+/+ BMDMs (Figures 7A
and S4A). We then analyzed the effect of miR-155 overexpres-
sion on cytokine release in tnc/BMDMs upon LPS stimulation.
In the absence of LPS, low-basal cytokine synthesis was de-
tected in untransfected and transfected cells. TNF-a production
in tnc/ BMDMs transfected with miR-155 precursor and stim-
ulated with LPS for 8 hr was significantly higher than in LPS-
activated tnc/ cells transfected with control precursor and
was equal to that of control tnc+/+ BMDMs (Figures 7B and
S4B). Thus, miR-155 overexpression rescued TNF-a release in
tnc/ BMDMs in response to LPS. Together, these data pro-
vide evidence that tenascin-C posttranscriptionally controls the
production of TNF-a in response to LPS via miR-155.
DISCUSSION
Since 1994, Polly Matzinger’s danger model, which suggested
that the immune system is designed to combat danger medi-
ated by infection and injury, rather than to merely recognize
nonself, has revolutionized our understanding of how the innate
Figure 4. Tenascin-C Posttranscriptionally Regulates the Synthesis of Specific Cytokine Subsets in BMDMs
(A) ELISA of TNF-a, IL-6, CXCL1, IL-10, IL-1b, IL-12, and TGF-b1 secreted by tnc+/+ and tnc/BMDMs stimulated for 1.5, 4, 8, 24, and 48 hr with 100 ng/ml LPS.
Data are from six to nine independent experiments (mean ± SEM). ****p < 0.0001, ***p < 0.001, **p < 0.01, and *p < 0.05.
(B) Quantitative RT-PCR analysis of TNF-a, IL-6, CXCL1, and IL-10mRNA in tnc+/+ and tnc/BMDMs stimulated for 0.5, 1, 1.5, 4, 8, 24, and 48 hr with 100 ng/ml
LPS. Results are presented relative to those of untreated BMDMs. Data are from four to five independent experiments (mean ± SEM).
See also Figure S3.
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Figure 5. Translation of Proinflammatory
Cytokines Is Inhibited in the Absence of
Tenascin-C
(A) ELISA of secreted and cellular TNF-a, IL-6,
and CXCL1 in tnc+/+ and tnc/ BMDMs stimu-
lated for 1.5, 4, 8, 24, and 48 hr with 100 ng/ml
LPS. Results are normalized to the cell number.
Data are from five to nine independent experi-
ments (mean ± SEM). ****p < 0.0001, ***p < 0.001,
**p < 0.01, and *p < 0.05.
(B) Total amounts of TNF-a, IL-6, and CXCL1 in
tnc+/+ and tnc/ BMDMs stimulated for 1.5, 4, 8,
24, and 48 hr with 100 ng/ml LPS. Results are
shown as the sum of the amounts of secreted and
cellular protein fractions normalized to the cell
number. Data are from five to nine independent
experiments (mean ± SEM). ***p < 0.001, **p <
0.01, and *p < 0.05.
(C) ELISA of cellular TNF-a, IL-6, and CXCL1 in
tnc+/+ and tnc/ BMDMs stimulated for 24 hr with
100 ng/ml LPS in the presence of 1 mg/ml brefeldin
A. Results are normalized to the cell number.
Data are from three independent experiments
(mean ± SEM). ****p < 0.0001 and *p < 0.05.immune system works (Matzinger, 1994). Both PAMPs and
DAMPs act as danger signals that trigger inflammation through
activation of PPRs, including TLRs (Gordon, 2002). Established
drivers of sterile inflammation, DAMPs have also been reported
to be specifically induced upon infection (Ehrchen et al., 2009;
Merline et al., 2011; Piccinini and Midwood, 2010; Wheeler
et al., 2009). However, little is known about their role in infec-
tion-induced TLR signaling. This study identified how control of
LPS-mediated TLR4 signaling is exerted by the proinflammatory
ECM glycoprotein tenascin-C. In particular, we show that tenas-
cin-C is an early LPS-responsive gene that is required for the
proinflammatory response to LPS in experimental sepsis.
Furthermore, we demonstrate that tenascin-C derived from
bone marrow-derived cells posttranscriptionally controls TNF-
a levels via regulation of miR-155 expression.
The induction of tenascin-C expression upon infection in vivo
(Pa¨a¨llysaho et al., 1993; Schenk et al., 1995; Tiitta et al., 1992)
and its transcriptional regulation by LPS in human myeloid
cells (Goh et al., 2010) prompted us to investigate whether
this DAMP plays a role in pathogenic inflammation. Using an
experimental model of LPS-induced systemic inflammation,
we showed that circulating tenascin-C increased rapidly in
septic tnc+/+ mice, peaking 90 min after LPS injection, long920 Cell Reports 2, 914–926, October 25, 2012 ª2012 The Authorsbefore the induction of HMGB1 release,
an established tissue injury marker in
sepsis (Wang et al., 1999). These data
support specific tenascin-C upregulation
by LPS-induced TLR4 signaling rather
than tissue damage-driven release of
tenascin-C. Indeed, we demonstrated
that tenascin-C is expressed at both
mRNA and protein level in LPS-activated
BMDMs, the major cellular players in
sepsis. In response to bacterial endo-toxins, macrophages promptly release proinflammatory cyto-
kines, including TNF-a, which is both crucial for effective innate
immunity and a key pathologic contributor to sepsis (Tracey
et al., 1987). However, septic tnc/ mice had significantly less
circulating TNF-a, a phenomenon that was reversed by alloge-
neic transplantation of bone marrow from tnc+/+ mice. Consis-
tent with low-circulating TNF-a, less plasma IL-6 and reduced
neutrophil infiltration to lungs and liver were observed in tnc/
mice after LPS injection compared to tnc+/+ mice. Furthermore,
tnc/ mice failed to induce release of HMGB1, a late mediator
of sepsis that is released by activated macrophages partly
through a TNF-a-dependent mechanism (Chen et al., 2004).
These data suggest that tenascin-C is an early-response gene
that regulates LPS-induced TLR4-mediated inflammation in vivo
operating upstream of TNF-a and HMGB1. This is further sup-
ported by our in vitro findings that tnc/ BMDMs secreted
significantly less TNF-a, IL-6, and CXCL1, upon stimulation
with LPS than tnc/ cells. This effect was specific because it
was not observed in other cytokine subsets, including IL-1b,
IL-12, or TGFb1. Furthermore, tenascin-C appears to specifically
control the switch from anti- to proinflammatory cytokine
programs downstream of TLR4 activation. In the absence of
tenascin-C, not only do BMDMs induce submaximal TNF-a
Figure 6. Tenascin-C Is Required for Induction of miR-155 in Activated BMDMs and in Septic Mice
(A) Microarray analysis of miRNA profile in tnc+/+ and tnc/ BMDMs stimulated for 8 hr with 100 ng/ml LPS. The heatmap shows suppression (green) and
induction (red) of expression as fold change on a log2 scale, relative to nonstimulated BMDMs (n = 3 mice per genotype).
(B and C) Expression of TLR-induced miRNAs in tnc+/+ and tnc/ BMDMs (identified in A) classified as early (B) and late (C) response genes (n = 3 per genotype;
mean ± SEM). **p < 0.01; ns, not significant.
(D) Time course analysis of miR-155, pri-miR-155, miR-146a, andmiR-21 expression in tnc+/+ and tnc/BMDMs stimulated for 4–72 hr (miR-155), 0.5–48 hr (pri-
miR-155), or 4–96 hr (miR-146a, miR-21) with 100 ng/ml LPS. RNA used in (A) (n = 3mice per group) and RNA isolated from BMDMs derived from two (miR-146a,
miR-21) and four (miR-155, pri-miR-155) additional mice per genotype was analyzed by quantitative RT-PCR (mean ± SEM). **p < 0.01 compared to tnc/
BMDMs at the same time point.
(E) Correlation of miR-155 expression with TNF-a synthesis in tnc+/+ and tnc/ BMDMs nonstimulated or stimulated with 100 ng/ml LPS for 4, 8, and 24 hr
(n = 5 mice per genotype; R = 1.0; p < 0.05).
(F) Quantitative RT-PCR analysis of miR-155 expression in spleen from tnc+/+ and tnc/ mice 1.5 hr after LPS injection (n = 3 per genotype; mean ± SEM).
*p < 0.05. Data are from two independent experiments.
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Figure 7. miR-155 Overexpression Rescues TNF-a Release in
Tnc/ BMDMs in Response to LPS
(A) Quantitative RT-PCR analysis of miR-155 expression in tnc+/+ un-
transfected BMDMs and tnc/ untransfected, mock transfected, and
transfected with control precursor or miR-155 precursor BMDMs stimulated
for 8 hr with 100 ng/ml LPS. Results are presented relative to those of
nonstimulated BMDMs (n = 3; mean ± SEM). *p < 0.05; ns, not significant.
Data are representative of four independent experiments each with cells
obtained from three mice per genotype.
(B) ELISA of TNF-a secreted by tnc+/+ untransfected BMDMs and tnc/
untransfected, mock transfected, and transfected with control precursor or
miR-155 precursor BMDMs stimulated for 8 hr with 100 ng/ml LPS (n = 6;
mean ± SEM). ***p < 0.001, **p < 0.01; ns, not significant. Data are from two in-
dependent experiments each with cells obtained from three mice per genotype.
See also Figure S4.levels, but they also secreted more IL-10, an anti-inflammatory
cytokine that is key to dampening the inflammatory response
to infection induced by TLR signaling. Thus, transient tenascin-
C expression promotes an initial proinflammatory response
that is later suppressed by IL-10 synthesis.
The ability to express biologically active cytokines on demand
is regulated at the transcriptional, translational, and posttran-
scriptional level. We have demonstrated here that tenascin-C
controls the synthesis of specific cytokine subsets in BMDMs
at the posttranscriptional level. Neither the extent of induction
nor the kinetics of expression of TNF-a, IL-6, CXCL1, and
IL-10 mRNA was significantly affected by tenascin-C. This
provides evidence that the impaired synthesis of proinflam-
matory cytokines is not at a gene transcription level. However,
exocytosis of cytokines to their site of action, which is mediated
predominantly by classic secretory pathways in activated
macrophages (Lacy and Stow, 2011), can also be the focus of
a regulatory event. By quantifying cytokines in the cellular
fraction, we found no significant difference in the intracellular
cytokine levels between LPS-activated tnc+/+ and tnc/
BMDMs. Thus, cellular trafficking of cytokines does not account
for reduced cytokine release in the absence of tenascin-C.
However, when protein transport from the ER to the Golgi was
prevented by brefeldin A during stimulation of tnc/ BMDMs
with LPS, intracellular accumulation of TNF-a was abrogated.
IL-6 and CXCL1 accumulation within the Golgi in tnc/ BMDMs
was significantly reduced when compared to tnc+/+ BMDMs.922 Cell Reports 2, 914–926, October 25, 2012 ª2012 The AuthorsTogether, these data suggest that tenascin-C is required for
effective translation of LPS-induced proinflammatory cytokines
in BMDMs.
A key finding of our study is the observation that tenascin-C
mediates an initial proinflammatory response to infection by
posttranscriptionally modulating the expression of the early
TLR-induced miRNA miR-155. This miRNA is processed from
the nonprotein-coding transcript of the bic gene, which is
extremely well conserved between humans and mice and is
highly expressed in lymphoid organs (Tam, 2001). Required for
the innate immune response to bacterial and viral infection,
miR-155 is strongly induced by LPS and type I interferons in
macrophages (O’Connell et al., 2007; Thai et al., 2007; Tili
et al., 2007). In line with this, by means of a miRNA screen and
validation analysis, we found that expression of both primary
transcript pri-miR155 and mature miR-155 was induced in
tnc+/+ BMDMs immediately after LPS stimulation. However, the
induction of mature miR-155 in tnc/ BMDMs was significantly
inhibited. This is underscored by the significantly lower miR-155
expression detected in vivo in the spleen of septic tnc/ mice.
Fundamental to the posttranscriptional control of gene expres-
sion, miRNAs have emerged as key regulators that fine-tune
TLR signaling (O’Neill et al., 2011). Emerging evidence points
to a proinflammatory role for miR-155 during TLR-mediated
inflammation. It suppresses the domain-containing inositol-50-
phosphatase 1 (SHIP1), a negative regulator of TLR-induced
responses, allowing the initial propagation of a proinflammatory
response (O’Connell et al., 2009). Moreover, miR-155 has been
proposed to increase the translation of TNF-a transcripts
either by acting at the 30 UTR of TNF-a mRNA to release its
self-inhibitory effects (Tili et al., 2007) or by increasing TNF-a
mRNA stability (Bala et al., 2011). In line with this, miR-155
overexpression in macrophages results in increased TNF-a
production, and miR-155 downregulation results in lower
TNF-a levels (Bala et al., 2011). Further evidence is provided
by in vivo studies; miR-155 transgenic mice have elevated serum
TNF-a and increased susceptibility to septic shock, whereas
miR-155-deficient B cells fail to produce TNF-a (Thai et al.,
2007; Tili et al., 2007). Consistent with this, we found a positive
correlation between miR-155 expression and TNF-a production
in tnc+/+ BMDMs upon LPS stimulation. Interestingly, in the
absence of tenascin-C, impaired TNF-a synthesis was parallel
to impaired miR-155 expression. Overexpressing miR-155 in
tnc/ BMDMs fully restored their ability to release TNF-a in
response to LPS. These data suggest that tenascin-C induced
by LPS in BMDMs uses miR-155 to modulate TNF-a levels.
The synthesis of IL-6, CXCL1, and IL-10 did not correlate with
miR-155 expression, nor was the release of these cytokines
rescued in tnc/ BMDMs by miR-155 overexpression. This is
in line with data that show that the effect of miR-155 on the
expression of cytokines other than TNF-a is likely to be indirect,
for example mediated via suppression of negative regulators of
cytokine-production suppressor of cytokine signaling 1
(SOCS1) (Androulidaki et al., 2009) and/or SHIP1 (Kurowska-
Stolarska et al., 2011; O’Connell et al., 2009), which are both
validated targets of miR-155, or as a result of impaired pro-
duction of TNF-a, which itself induces the expression of both
IL-6 and CXCL1. Finally, tenascin-C appears to specifically
control the induction ofmiR-155 without affecting the expression
of other LPS-responsive miRNAs that have been functionally
linked to TLR signaling, including miR-146a and miR-21 (Sheedy
et al., 2010; Taganov et al., 2006).
We previously found high tenascin-C levels in inflamed
rheumatoid joints, where it is specifically expressed by synovial
fibroblasts and myeloid cells (Goh et al., 2010). We showed that
tenascin-C induces cytokine synthesis in both human and
murine macrophages and in rheumatoid arthritis (RA) synovial
fibroblasts via activation of TLR4 (Midwood et al., 2009). Tenas-
cin-C also induces cytokine synthesis in human chondrocytes
in a TLR4-dependent manner (Patel et al., 2011). Other studies
report that murine myeloid cells require a9-integrin expression
to be activated by tenascin-C (Kanayama et al., 2009, 2011).
These data suggest that a number of receptors can play a role
in tenascin-C-driven inflammation. We found that the fibrin-
ogen-like globe of tenascin-C activates TLR4 (Midwood et al.,
2009), whereas a9-integrin was activated by the third fibronectin
type III-like repeat of tenascin-C (Kanayama et al., 2011). Data
from these studies, carried out in the absence of cell-activating
levels of LPS, imply that within one tenascin-C molecule exist
at least two proinflammatory domains with distinct mecha-
nisms. Data presented here show that upon cell stimulation
with LPS, tenascin-C sustains TNF-a synthesis by controlling
miR-155 expression. It is not yet known how tenascin-C regu-
lates miR-155 levels. Secreted tenascin-C may activate TLR4,
a9-integrin, or other cell surface receptors. However, addition
of soluble tenascin-C at a concentration comparable to that
made by LPS-stimulated tnc+/+ BMDMs (<10 ng/ml) did not
rescue defects in tnc/ BMDM cytokine synthesis. Moreover,
high concentrations of soluble tenascin-C (up to 1 mg/ml)
inhibited cytokine synthesis (Figure S4C). These data indicate
that, rather than amplifying activation of TLR4 by LPS, adding
high concentrations of exogenous tenascin-C prevents LPS
activation of TLR4. This may reflect competition for the same
receptor by the two stimuli. Together, these results indicate
that addition of soluble tenascin-C is not sufficient to rescue
LPS-mediated cytokine synthesis in BMDMs derived from te-
nascin-C-deficient mice. Thus, ligation of a receptor by soluble
tenascin-C at the cell surface may not be responsible for stimu-
lating miR-155 expression and sustaining cytokine production
during LPS activation. It may be that receptor activation requires
tenascin-C assembly into a cell-associated matrix; this may
function as a scaffold essential for receptor ligation or for recruit-
ment of potential coreceptor(s). Alternatively, in light of emerging
evidence highlighting a role for the 30 UTR of matrix molecule
mRNAs in controlling miRNA function (Jeyapalan and Yang,
2012; Lee et al., 2009), noncoding regions of the tenascin-C
gene may drive miRNA biogenesis.
These data raise a number of questions, foremost of which is
why tenascin-C should exhibit multiple proinflammatory modes
of action. The answer may lie in the role of tenascin-C in driving
both pathogenic and sterile inflammation. During acute inflam-
matory responses to LPS, tenascin-C acts swiftly to sustain
cytokine synthesis at the posttranscriptional level, enabling
a robust, immediate response to microbial threat. Upon sterile
tissue injury, however, the ability of tenascin-C to drive de
novo cytokine synthesis, via activation of TLR4 or integrins,Censures effective tissue repair but that sterile inflammation also
contributes to chronicity in diseases such as RA.
Both tenascin-C and miR-155 come into play during infection,
promoting innate immune responses that culminate in the syn-
thesis of proinflammatory cytokines. Physiologically low and
specifically regulated, their expression is transiently induced by
LPS in innate immune cells in a NF-kB-dependent manner
(Bala et al., 2011; Goh et al., 2010; Rai et al., 2008). Their dysre-
gulation, however, can lead to both cancerous phenotypes
(Calin and Croce, 2006; Chiquet-Ehrismann and Chiquet, 2003)
and inflammatory and autoimmune diseases, such as sepsis
(Schenk et al., 1995; Tili et al., 2007) and RA (Midwood et al.,
2009; Stanczyk et al., 2008). Pharmacological inhibition of
LPS-induced miR-155 expression by glucocorticoids in macro-
phages has been reported by Zheng et al. (2012). Notably, tenas-
cin-C expression was also inhibited by glucocorticoids in bone
marrow stromal cells and fibroblasts (Ekblom et al., 1993).
Furthermore, both tenascin-C and miR-155 have been shown
to affect the ability of the innate immune system to prime adap-
tive immune responses. In particular, they promote dendritic
cell-mediated polarization of Th17 lymphocytes during inflam-
mation (O’Connell et al., 2010; Ruhmann et al., 2012).
In conclusion, our study has identified how tenascin-C control
of miR-155 levels regulates the inflammatory axis upon patho-
genic activation of TLR4. These data highlight how endogenous
danger signals are required for optimal cytokine synthesis in
response to PAMP activation of TLRs. This finding provides
insight into the positive regulation of TLR4 signaling and DAMP
function, which goes beyond sterile inflammation and defines
DAMPs additionally as key controllers of nonsterile inflam-
mation. Understanding which molecular inputs are required for
optimal induction of cytokines upon TLR activation may refine
our strategies to manipulate excessive inflammation.EXPERIMENTAL PROCEDURES
Mice
Littermate tnc+/+ and tnc/ mice were from heterozygous breeding pairs on
a 129/SvJ background (Saga et al., 1992). All mice were male aged
8–12 weeks, except for bone marrow transplantation, which were female
aged 6–8 weeks. For the generation of BMDMs, bone marrow was flushed
from tibias and femurs of tnc+/+ and tnc/mice, and erythrocytes were lysed
with Red Blood Cell Lysis Buffer (Sigma-Aldrich). The resulting cells were
cultured in DMEM (PAA) supplemented with 20% FCS (GIBCO), 1% Antibi-
otic-Antimycotic solution (PAA), and 50 mM b-mercaptoethanol (Invitrogen)
containing 100 ng/ml recombinant murine M-CSF (PeproTech). After 7 days,
adherent cells were washed, replated, and stimulated with LPS alone
(100 ng/ml; Enzo Life Sciences) or with brefeldin A (1 mg/ml; Sigma-Aldrich).
To avoid cell toxicity, we treated BMDMs with brefeldin A for the last 8 hr of
incubation with LPS. For the generation of thioglycollate-elicited peritoneal
macrophages, tnc+/+ and tnc/ mice were injected intraperitoneally with
1 ml thioglycollate (3% w/v; Sigma-Aldrich). Peritoneal exudates were
collected 5 days after with PBS, and cells were analyzed by FACS. For analysis
of LPS-induced sepsis, tnc+/+ and tnc/ mice were injected intraperitoneally
with LPS from E. coli 055:B5 (8mg/kg; Sigma-Aldrich). Mice were observed for
8 hr. Body weight, mobility, uveitis, respiration, fur ruffling, and diarrhea were
recorded at 0, 1.5, 4, and 8 hr after LPS injection. Mobility impairment was
graded using an arbitrary scale where 0 = none, 1 = mild (reduced and slower
movement), 2 = moderate (movement upon stimulation), and 3 = severe (no
movement). Mice were killed after 1.5, 4, or 8 hr, and plasma and tissues
were collected. All procedures were approved by the UK Home Office.ell Reports 2, 914–926, October 25, 2012 ª2012 The Authors 923
ELISA
ELISAs for TNF-a, IL-6, IL-8 (R&D), IL-1b (eBioscience), IL-12, TGF-b1, IL-10,
(BD Biosciences), HMGB1, and TN-C (IBL) were used to quantify secreted
and cell-associated proinflammatory mediators in plasma, cell supernatants,
and total protein extracts, respectively. Extracts were prepared by lysing cells
(1 3 106) with 0.1 ml RIPA buffer containing a protease inhibitor cocktail
(Sigma-Aldrich).
Immunohistochemical Analysis
Formalin-fixed tissues from tnc+/+ and tnc/ mice were paraffin embedded,
cut into 4 mm sections, and stained for neutrophil elastase (MCA7771G;
AbD Serotec). Immunostaining specificity was confirmed by omitting the
primary antibody or using a nonimmune rat IgG2a (MCA1212; AbD Serotec).
Neutrophil elastase+ cell number was determined by counting cells in five
different areas of the total tissue section.
Immunoblot
Plasma samples from tnc+/+ and tnc/ mice were resolved by SDS-PAGE
and analyzed by western blotting using goat anti-tenascin-C polyclonal Ab
(AF3358; R&D Systems).
Bone Marrow Transplantation
Each tnc/ and tnc+/+ female recipient mouse was exposed to a single dose
of 9 Gy at 80 cGy/min radiation in a g irradiator (Nordion) and, 3 hr later, intra-
venously injected with whole bone marrow cells isolated from one tnc/ or
tnc+/+ male mouse resuspended in 0.2 ml PBS. Transplanted mice received
antibiotic orally for 11 weeks (2.5% Baytril; Bayer). The degree of donor
engraftment was assessed as described previously by Wang et al. (2002).
Genomic DNA was extracted from peripheral blood cells of female recipient
and control mice using a QIAamp DNA Blood Mini kit (QIAGEN). DNA samples
were analyzed for the presence of the Y chromosome by two-standard curve
method based on quantitative real-time PCR in a Corbett Rotor-gene 6000
machine (Corbett Research) with TaqMan primers and probe designed to
detect the TSPY gene (forward 50-TCCTTGGGCTCTTCATTATTCTTAAC-30;
reverse 50-GAGAACCACGTTGGTTTGAGATG-30; probe 6FAM-TCCTGGAT
CAGAGTGGCTTACCCAGG-TAMRA; Applied Biosystems). Standard curves
were obtained by mixing male and female DNA from nontreated control
mice. Samples were standardized against a mouse GAPDH genomic primer/
probe set (Applied Biosystems). Samples were calibrated against DNA from
male-nontreated control mouse.
RNA Extraction and Quantitative Real-Time PCR
Total RNA was extracted from cells (1 3 106) using a RNeasy Mini Kit
(QIAGEN). cDNA was synthesized from equivalent amounts of RNA with
AffinityScript reverse transcriptase and oligo(dT) primer (Stratagene). Quanti-
tative real-time PCR was performed in a Corbett Rotor-gene 6000 machine
with TaqMan primer sets for mouse tenascin-C (Mm00495662_m1), TNF-a
(Mm99999068_m1), IL-6 (Mm00446190_m1), CXCL1 (Mm00433859_m1),
IL-10 (Mm00439614_m1), CD11b (Mm00434455_m1), CD68 (Mm00839636_
g1), F4/80 (Mm00802529_m1), and HPRT1 (Mm00446968_m1) (Applied
Biosystems). For miRNA analysis, total RNA including small RNA was ex-
tracted from cells (2 3 106) using TRIzol (Invitrogen). For mature miRNA
detection, RNA was reverse transcribed using the TaqMan miRNA reverse-
transcription kit, including the miRNA-specific primers, followed by real-time
PCR with individual miRNA TaqMan assays for the endogenous reference
RNA RNU6B, miR-155, miR-146a, and miR-21 (Applied Biosystems). For
pri-miRNA detection, RNA was reverse transcribed with AffinityScript reverse
transcriptase and random primers (Stratagene), followed by real-time PCR
with TaqMan primer sets for mouse pri-miR155 (Mm03306395_pri) and
HPRT1 (Applied Biosystems). Changes in expression were calculated by the
change-in-threshold (DDCT) method with HPRT1 and RNU6B as endogenous
controls for gene expression and miRNA analysis, respectively, and were
normalized to results obtained with untreated cells.
miRNA Array
The expression profile of 375 miRNAs was analyzed with TaqMan LowDensity
Arrays in an ABI 7900HT (Applied Biosystems). Total RNA was extracted from924 Cell Reports 2, 914–926, October 25, 2012 ª2012 The Authorscells with TRIzol. RNA integrity was analyzed using an Agilent RNA 6000
Nano kit and an Agilent 2100 bioanalyzer (Agilent Technologies). cDNA was
synthesized with a TaqMan miRNA reverse-transcription kit and Megaplex
RT primers and was followed by real-time PCR with a TaqMan universal
PCRmaster mix and TaqMan array rodent miRNA cards (Applied Biosystems).
Data were analyzed with SDS software (Applied Biosystems).
Transient Transfection
For transfection of miRNA, 23 106 tnc/ BMDMs were transfected with 5 nM
negative control precursor or miR-155 precursors with siPORT NeoFX trans-
fection agent (Ambion) for 8 hr. Cells were allowed to recover for 24 hr before
treatment with LPS for 8 hr.
Statistical Analysis
Statistical analysis was performed using Student’s t test, one-way ANOVA
with Dunnett’s multiple comparison posttest, or two-way ANOVA with Bonfer-
roni posttest where appropriate; correlation was assessed with Spearman’s
rho test (Prism 5; GraphPad Software).
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